Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Cash & Equivalents

Cash & Equivalents at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$833.99M-43.7%
Assembly Biosciences logo
Assembly BiosciencesASMB
$31.12M+32.9%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$23.71M-36.1%
Wave Life Sciences logo
Wave Life SciencesWVE
$544.59M+124%

Other financials

Income statement

See full
Revenue$1.2B+96.4%
Gross profit$959.7M+83.1%
Operating income$268.6M+1,386%
Net income$206.0M+1,229%
EPS (diluted)$1.51+1,179%

Balance sheet

See full
Total debt$263.7M-4.5%
Total equity$1.1B+152%
Total assets$5.1B+21.7%

Cash flow

See full
Operating cash flow$70.5M+159%
CapEx$21.8M+143%
Free cash flow$48.7M+138%

Valuation

See full
Market cap$40.19B+0.6%
Enterprise value$38.74B-0.8%
P/E80×—
P/S9.4×-6.8×

Profitability

See full
Gross margin81%-5.3pp
Operating margin17.5%+14.4pp
Net margin11.7%+8.0pp
FCF margin15%+12.7pp

Returns & leverage

See full
Return on equity66.9%—
Debt / equity0.2×-0.4×
Current ratio3.1×+0.1×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alnylam Pharmaceuticals's cash & equivalents?
Alnylam Pharmaceuticals (ALNY) reported cash & equivalents of $1.71B in Q1 2026.
How has Alnylam Pharmaceuticals's cash & equivalents changed year-over-year?
Alnylam Pharmaceuticals's cash & equivalents increased by 67.5% year-over-year, from $1.02B to $1.71B.
What is the long-term trend for Alnylam Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's cash & equivalents has grown at a 27.2% compound annual growth rate (CAGR), from $499.05M to $1.66B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.